Phase I/II Study of the P13Kinase Inhibitor BKM120 Given in Combination With Panitumumab in Patients With Metastatic or Advanced RAS-Wild Type Colorectal Cancer
Active, no longer recruiting
Phase of Trial: Phase I/II
Latest Information Update: 15 Mar 2017
At a glance
- Drugs Buparlisib (Primary) ; Panitumumab
- Indications Colorectal cancer
- Focus Adverse reactions
- 07 Jun 2017 Biomarkers information updated
- 29 Nov 2016 Planned End Date changed from 1 Sep 2016 to 1 Jun 2017.
- 01 Mar 2016 Planned End Date changed from 1 Dec 2015 to 1 Sep 2016 as per ClinicalTrials.gov record.